



P300 as an auxiliary method in clinical practice: A review of literature

Marina Titlic^{1,2}, Mario Mihalj¹, Amira Beganović Petrović³, Enra Suljić³

¹Department of Neurology, Split University Hospital, Split, Croatia, ²School of Medicine, University of Split, Split, Croatia, ³Department of Neurology, Sarajevo University Hospital, Sarajevo, Bosnia and Herzegovina

ABSTRACT

Cognitive functions can be assessed and followed up over a period of time with cognitive evoked potentials (CEP) P300. In this context, brainstem auditory evoked potentials (BAEP) are most commonly used, but visual evoked potentials (VEP) are utilized as well. The research in this area has demonstrated that these techniques could be used as a supplemental method in diagnostics of numerous diseases such as Alzheimer's disease, mild cognitive impairment, vascular dementia, epilepsy, craniocerebral trauma, Parkinson's disease, multiple sclerosis, and other degenerative diseases. In addition, P300 can also be used as an auxiliary method in the diagnostics of mental disorders conditions such as schizophrenia, panic disorders, narcotic drug addiction, nicotine, alcoholism, etc. The method assists in monitoring the course of diseases leading to encephalopathy, such as liver and kidney damage and grave anaemia. The advantages of P300 testing are easy application, non-invasiveness, and an unlimited number of potential applications. Moreover, the results obtained with this method are measurable and can be compared.

Keywords: P300; cognitive; clinical practice

INTRODUCTION

Neuropsychological tests are applied in assessing cognitive, cortical functions in patients with neurological and mental diseases, brain trauma, and damage resulting from other diseases (1-3). Event-related potential (ERP) is a non-invasive electrophysiological method. It can be used to assess different aspects of human cognitive information processing. ERP components such as auditory evoked P300,

associated with cognitive processes (i.e., attention and orientation), show low amplitude and long latency in acute and chronic diseases (4-6). P300 testing is an unbiased and non-invasive method, standardized for assessing cognitive processes (7-10). We have reviewed the existing literature in this field to better understand the role of P300 testing in diagnostics of different diseases.

Review of literature

We performed a systematic literature search and review of publications identified in the MEDLINE database (searched through September 2009). The search term was "P300, cognitive", and the search was limited to clinical trials and articles in English.

*Corresponding author: Marina Titlic,
Department of Neurology, University of Split, Spinciceva 1,
Split 21000, Croatia. E-mail: marina.titlic@gmail.com

Submitted: 15 July 2016/Accepted: 19 November 2016

DOI: <http://dx.doi.org/10.17532/jhsci.2016.304>



The search was extended by the review of bibliographies from pertinent original reports and review articles. The research included 1212 references on P300.

P300 testing has been demonstrated to be a method of choice in differential diagnostic assessment of neurological and psychiatric diseases (Table 1). Clinical research showed significant changes in P300 parameters, such as lowered amplitude and extended latency, in patients with dementia, Alzheimer's disease, and mild cognitive impairment [MCI] (11-19). A smaller number of studies indicated changes in P300 in patients with epilepsy, and in those taking antiepileptic drugs (10,20). A few studies indicated specific changes in amplitude and latency of P300 in clinically isolated syndrome and multiple sclerosis, as well as effects of interferon beta-1b to cognitive functions, even the P300 characteristics (21-23). Some studies indicated changes in P300 characteristics in patients with Parkinson's disease (the changes correlated with the degree of the disease determined according to the Hoehn and Yahr scale), growth hormone deficiency, Huntington's disease, Tourette syndrome, and narcolepsy (2,9,24-27). Changes of P300 characteristics, lowered amplitude, and extended latency

have also been noticed in schizophrenia (28-36), post-traumatic stress disorder (36,37,40), endogenous psychoses (38-41), panic disorder (42-45), and depressive patients (46,47). Additionally, a few papers described changes of P300 in impulsive aggressive criminals and obsessive-compulsive disorder (48,49).

Cognitive damage often results from craniocerebral trauma. The damage and gravity dysfunction are assessed by neuropsychological and neurophysiological analysis, where cognitive evoked potentials (CEP) P300 is among the preferred methods (50-53).

Some studies reported changes in P300 amplitude and latency in cases of chronic consumption of nicotine, alcohol, as well as cannabis, opioids, cocaine, and ecstasy (Table 2) (8,54-60).

Isolated research has been performed on CEP P300 in patients with epilepsy taking different antiepileptic drugs, such as: topiramate, valproate, and lamotrigine (61-63). These studies were based on measuring and comparing CEP P300 parameters while the patients were taking the drugs.

Cognitive damage in some systemic diseases can be assessed with CEP P300 (64-78). Improvements in

TABLE 1. Neurological and psychiatric diseases with confirmed changes of P300 wave parameters

Disease	Studies
Dementia	Uemura et al. (11), Egerházi et al. (17), Egerházi et al. (18)
Alzheimer's disease	Bennys et al. (12), Juckel et al. (14), Yener et al. (15), van Deursen et al. (16), Egerházi et al. (17), Egerházi et al. (18)
Mild cognitive impairment	Bennys et al. (12), Golob et al. (13), van Deursen et al. (16), Egerházi et al. (17), Egerházi et al. (18), Pappaliagkas et al. (19)
Epilepsy	Zgorzalewicz (10), Ozmenek et al. (20)
Clinically isolated syndrome	Kocer et al. (21)
Multiple sclerosis	Magnié et al. (22), Flechter et al. (23)
Parkinson's disease	Hayashi et al. (24)
Growth hormone deficiency	Tanriverdi et al. (25), Braverman et al. (26)
Huntington's disease	Beste et al. (9)
Narcolepsy	Saletu et al. (2)
Tourette syndrome	Thibault et al. (27)
Schizophrenia	Ford et al. (28), van der Stelt and Belger (29), Takahashi et al. (30), Zhang et al. (31), Higuchi et al. (32), Wood et al. (33), Özgürdal et al. (1), Sumiyoshi et al. (34), Turetsky et al. (35), Galletly et al. (36), Veltmeyer et al. (37)
Endogenous psychoses	Lebedeva et al. (38), Lebedeva et al. (39), Bramon et al. (40)
Post-traumatic stress disorder	Veltmeyer et al. (37), Shucard et al. (41)
Panic disorder	Tuter (42), Gordeev (43), Gordeev (44), Gordeev (45)
Depression	Coullaut-Valera Garcia et al. (46), Zhang et al. (47)
Impulsive aggressive behavior	Zukov et al. (48)
Obsessive-compulsive disorder	Gohle et al. (49)

the treatment and recovery can be followed in the same way. So far, changes in P300 characteristics, amplitude, and latency have been monitored in the following systemic diseases: anaemia, hepatic insufficiency, diabetes mellitus type 1, hypothyroidism, chronic obstructive pulmonary disease (COPD), organophosphorus insecticide poisoning, and HIV-1 neurologically asymptomatic seropositive individuals (Table 3).

DISCUSSION

Cognitive abilities include a number of qualitative characteristics that can be assessed with different neuropsychological tests. Recently, neurophysiological tests with CEP P300 are gaining attention (79-81). During the testing procedure, both auditory and visual stimuli are used. These are referred to as brainstem auditory evoked potentials (BAEP) and visual evoked potentials (VEP), and BAEP are used more frequently. In addition, comparative analysis of neuropsychological and neurophysiological P300 tests showed a statistically significant correlation, with high specificity and sensitivity (79-83). Changes of CEP P300 are characterized by extended latency and low wave amplitude. Numerous studies showed alterations of CEP P300 in neurological and psychiatric diseases, as well as consequences of traumatic

damages of the brain, that is, craniocerebral injuries (11-53). Different substances that cause addiction, from alcohol and nicotine to various opiates, lead to changes in cognitive functions, including changes in P300 parameters, due to brain damage (54-60). Moreover, with P300 testing, damage of cognitive functions resulting from taking different medicines, especially antiepileptic drugs, can also be monitored (61-63). Additionally, P300 characteristics help diagnosing cognitive damage resulting from systemic diseases, such as anaemia, uremia (renal insufficiency), hepatic encephalopathy, systemic lupus erythematosus, diabetes mellitus, hypothyreosis, as well as COPD (64-76). Moreover, cognitive function damage in patients with HIV-1 neurologically asymptomatic seropositive can be assessed with P300 testing (78). Finally, changes of P300 parameters are observed in organophosphorus insecticide poisoning (77).

CEP P300 tests are easy to apply, can be repeated often, there are no unwanted side effects or radiation, and the application is very simple. Also, the test is unbiased and a tested individual cannot influence the results. The test results (wave amplitude and latency) are expressed numerically. Therefore, the results can be easily compared at various stages of a disease, and the brain damage as well as the healing process can be monitored. All the mentioned above indicate that CEP P300 is a method of choice in differential diagnostics of cognitive functions. This is a preferred supplemental method in diagnostics of cognitive damage in clinical practice.

CONCLUSION

CEP P300 testing is a simple, quantitative, diagnostic method used in diagnosing cognitive damage in

TABLE 2. Substances that cause addiction and results in altered P300

Addictive substances	Studies
Nicotine	Müller et al. (8), Guney et al. (54)
Alcohol	Naziel et al. (55), Maurage et al. (56)
Cannabis	Roser et al. (57)
Opioid	Singh et al. (58)
Cocaine	Gooding et al. (59)
Ecstasy	de Sola et al. (60)

TABLE 3. Systemic diseases that cause damage to cognitive functions measurable with P300

Disease	Studies
Anaemia	Otero et al. (64), Khedr et al. (65), Kececi et al. (66)
Hepatic encephalopathy	Reeves et al. (67), Teodoro et al. (68), Guerit et al. (69)
Neuropsychiatric systemic lupus erythematosus	Mostafa et al. (70), Buca et al. (71)
Uremia	Madan et al. (72)
Diabetes mellitus type 1	Cooray et al. (73)
Hypothyroidism	Naziel et al. (74), Anjana et al. (75)
Chronic obstructive pulmonary disease	Kirkil et al. (76)
Organophosphorus insecticide poisoning	Dassanayake et al. (77)
HIV-1 seropositive subjects	Amador Romero et al. (78)

clinical practice. The main advantage of this method compared to other diagnostic methods is the ability to compare the measurement results easily and to monitor the progress of disease.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

REFERENCES

- Ozğürdal S, Gudowski Y, Witthaus H, Kawohl W, Uhl I, Hauser M, et al. Reduction of auditory event related P300 amplitude in subjects with at-risk mental state for schizophrenia. *Schizophr Res* 2008;105(3):272-8. <https://doi.org/10.1016/j.schres.2008.05.017>.
- Saletu M, Anderet P, Saletu-Zyhlarz GM, Mandl M, Zeithofer J, Saletu B. Event-related-potential low-resolution brain electromagnetic tomography (ERP-LORETA) suggests decreased energetic resources for cognitive processing in narcolepsy. *Clin Neurophysiol* 2008;119(8):1782-94. <https://doi.org/10.1016/j.clinph.2008.04.297>.
- Gómez CM, Flores A, Digiaco MR, Ledesma A, González-Rosa J. P3a and P3b components associated to the neurocognitive evaluation of invalidly cued targets. *Neurosci Lett* 2008;430(2):181-5. <https://doi.org/10.1016/j.neulet.2007.10.049>.
- Xu G, Zhang Y, Hozu H, Yan W. Event-related potential studies of attention to shape under different stimuli tasks. *Conf Proc IEEE Eng Med Biol Soc* 2006;Suppl:6618-21.
- Polich J. Updating P300: An integrative theory of P3a and P3b. *Clin Neurophysiol* 2007;118(10):2128-48. <https://doi.org/10.1016/j.clinph.2007.04.019>.
- Vanhau denhuyse A, Laureys S, Perrin F. Cognitive event-related potentials in comatose and post-comatose states. *Neurocrit Care* 2008;8(2):262-70. <https://doi.org/10.1007/s12028-007-9016-0>.
- Rektor I, Brázdil M, Nestržil I, Bares M, Daniel P. Modifications of cognitive and motor tasks affect the occurrence of event-related potentials in the human cortex. *Eur J Neurosci* 2007;26(5):1371-80. <https://doi.org/10.1111/j.1460-9568.2007.05713.x>.
- Müller BW, Specka M, Steinchen N, Zerbin D, Lodemann E, Finkbeiner T, et al. Auditory target processing in methadone substituted opiate addicts: The effect of nicotine in controls. *BMC Psychiatry* 2007;7:63. <https://doi.org/10.1186/1471-244X-7-63>.
- Beste C, Saft C, Güntürkün O, Falkenstein M. Increased cognitive functioning in symptomatic Huntington's disease as revealed by behavioral and event-related potential indices of auditory sensory memory and attention. *J Neurosci* 2008;28(45):11695-702. <https://doi.org/10.1523/JNEUROSCI.2659-08.2008>.
- Zgorzalewicz M. Long latency auditory evoked potentials in schoolchildren and adolescents with epilepsy. *Przegł Lek* 2006;63(Suppl 1):8-13.
- Uemura J, Hoshiyama M. Variability of P300 in elderly patients with dementia during a single day. *Int J Rehabil Res* 2007;30(2):167-70. <https://doi.org/10.1097/MRR.0b013e32813a2e6f>.
- Bennys K, Portet F, Touchon J, Rondouin G. Diagnostic value of event-related potentials N200 and P300 subcomponents in early diagnosis of Alzheimer's disease and mild cognitive impairment. *J Clin Neurophysiol* 2007;24(5):405-12. <https://doi.org/10.1097/WNP.0b013e32815068d5>.
- Golob EJ, Irimajiri R, Starr A. Auditory cortical activity in amnesic mild cognitive impairment: Relationship to subtype and conversion to dementia. *Brain* 2007;130(Pt 3):740-52. <https://doi.org/10.1093/brain/awl375>.
- Juckel G, Clotz F, Frodl T, Kawohl W, Hampel H, Pogarell O, et al. Diagnostic usefulness of cognitive auditory event-related P300 sub-components in patients with Alzheimers Disease? *J Clin Neurophysiol* 2008;25(3):147-52. <https://doi.org/10.1097/WNP.0b013e3281727c95>.
- Yener G, Güntekin B, Baser E. Event-related delta oscillatory responses of Alzheimer patients. *Eur J Neuro* 2008;15(6):540-7. <https://doi.org/10.1111/j.1468-1331.2008.02100.x>.
- van Deursen JA, Vuurman EF, Smits LL, Verhey FR, Riedel WJ. Response speed, contingent negative variation and P300 in Alzheimer's disease and MCI. *Brain Cogn* 2009;69(3):592-9. <https://doi.org/10.1016/j.bandc.2008.12.007>.
- Egerházi A, Glaub T, Balla P, Berecz R, Degrell I. P300 in mild cognitive impairment and in dementia. [Article in Hungarian]. *Psychiatr Hung* 2008;23(5):349-57.
- Egerházi A. The early diagnosis and differential diagnosis of Alzheimer's disease with clinical methods. *Orv Hetil* 2008;149(51):2433-40. <https://doi.org/10.1556/OH.2008.28429>.
- Pappaliagkas V, Kimiskidis V, Tsolaki M, Anogiannakis G. Usefulness of event-related potentials in the assessment of mild cognitive impairment. *BMC Neurosci* 2008;9:107. <https://doi.org/10.1186/1471-2202-9-107>.
- Ozmenek OA, Nazliel B, Leventoglu A, Bilir E. The role of event related potentials in evaluation of subclinical cognitive dysfunction in epileptic patients. *Acta Neurol Belg* 2008;108(2):58-63.
- Kocer B, Unal T, Nazliel B, Biyikli Z, Yesilbudak Z, Karakas S, et al. Evaluating sub-clinical cognitive dysfunction and event-related potentials (P300) in clinically isolated syndrome. *Neuro Sci* 2008;29(6):435-44. <https://doi.org/10.1007/s10072-008-1020-4>.
- Magnié MN, Bensa C, Laloux L, Bertogliati C, Faure S, Lebrun C. Contribution of cognitive evoked potentials for detecting early cognitive disorders in multiple sclerosis. *Rev Neurol (Paris)* 2007;163(11):1065-74. [https://doi.org/10.1016/S0035-3787\(07\)74179-6](https://doi.org/10.1016/S0035-3787(07)74179-6).
- Flechter S, Vardi J, Finkelsein Y, Pollak L. Cognitive dysfunction evaluation in multiple sclerosis patients treated with interferon beta-1b: An open-label prospective 1 year study. *Isr Med Assoc J* 2007;9(6):457-9.
- Hayashi R, Hanyu N, Tamaru F. Cognitive impairment in Parkinson's disease: A 6 year follow-up study. *Parkinsonism Relat Disord* 1998;4(2):81-5. [https://doi.org/10.1016/S1353-8020\(98\)00018-2](https://doi.org/10.1016/S1353-8020(98)00018-2).
- Tanriverdi F, Yapislilar H, Karaca Z, Unluhizarci K, Suer C, Kelestimir F. Evaluation of cognitive performance by using P300 auditory event related potentials (ERPs) in patients with growth hormone (GH) deficiency and acromegaly. *Growth Horm IGF Res* 2009;19(1):24-30. <https://doi.org/10.1016/j.ghir.2008.05.002>.
- Braverman ER, Chen TJ, Prihoda TJ, Songntag W, Meshkin B, Downs BW, et al. Plasma growth hormones, P300 event-related potential and test of variables of attention (TOVA) are important neuroendocrinological predictors of early cognitive decline in a clinical setting: Evidence support by structural equation modeling (SEM) parameter estimates. *Age (Dordr)* 2007;29(2-3):55-67. <https://doi.org/10.1007/s11357-007-9030-3>.
- Thibault G, O'Connor KP, Stip E, Lavoie ME. Electrophysiological manifestations of stimulus evaluation, response inhibition and motor processing in Tourette syndrome patients. *Psychiatry Res* 2009;167(3):202-20. <https://doi.org/10.1016/j.psychres.2008.03.02>.
- Ford JM, Krystal JH, Mathalon DH. Neural synchrony in schizophrenia: From networks to new treatments. *Schizophr Bull* 2007;33(4):848-52.

- <https://doi.org/10.1093/schbul/sbm062>.
29. van der Stelt O, Belger A. Application of electroencephalography to the study of cognitive and brain functions in schizophrenia. *Schizophr Bull* 2007;33(4):955-70.
<https://doi.org/10.1093/schbul/sbm016>.
 30. Takahashi S, Tanabe E, Sakai T, Matsuura M, Matsushima E, Obayashi S, et al. Relationship between exploratory eye movement, P300, and reaction time in schizophrenia. *Psychiatry Clin Neurosci* 2008;62(4):396-403.
<https://doi.org/10.1111/j.1440-1819.2008.01817.x>.
 31. Zhang Y, Lehmann M, Shobeiry A, Höfer D, Johannes S, Emrich HM, et al. Effects of quetiapine on cognitive functions in schizophrenic patients: A preliminary single-trial ERP analysis. *Pharmacopsychiatry* 2009;42(4):129-34.
<https://doi.org/10.1055/s-0028-1112133>.
 32. Higuchi Y, Sumiyoshi T, Kawasaki Y, Matsui M, Arai H, Kurachi M. Electrophysiological basis for the ability of olanzapine to improve verbal memory and functional outcome in patients with schizophrenia: A LORETA analysis of P300. *Schizophr Res* 2008;101(1-3):320-30.
<https://doi.org/10.1016/j.schres.2008.01.020>.
 33. Wood SM, Potts GF, Martin LE, Kothmann D, Hall JF, Ulanday JB. Disruption of auditory and visual attention in schizophrenia. *Psychiatry Res* 2007;156(2):105-16.
<https://doi.org/10.1016/j.psychres.2007.04.014>.
 34. Sumiyoshi T, Higuchi Y, Itoh T, Matsui M, Arai H, Suzuki M, et al. Effect of persiprone on P300 electrophysiological activity and social cognition in schizophrenia: A three-dimensional analysis with sloreta. *Psychiatry Res* 2009;172(3):180-3.
<https://doi.org/10.1016/j.psychres.2008.07.005>.
 35. Turetsky BI, Bilker WB, Siegel SJ, Kohler CG, Gur RE. Profile of auditory information-processing deficits in schizophrenia. *Psychiatry Res* 2009;165(1-2):27-37.
<https://doi.org/10.1016/j.psychres.2008.04.013>.
 36. Galletly CA, McFarlane AC, Clark R. Differentiating cortical patterns of cognitive dysfunction in schizophrenia and posttraumatic stress disorder. *Psychiatry Res* 2008;159(1-2):196-206.
<https://doi.org/10.1016/j.psychres.2007.04.001>.
 37. Veltmeyer MD, Clark CR, McFarlane AC, Moores KA, Bryant RA, Gordon E. Working memory function in post-traumatic stress disorder: An event-related potential study. *Clin Neurophysiol* 2009;120(6):1096-1106.
<https://doi.org/10.1016/j.clinph.2009.03.024>.
 38. Lebedeva IS, Kaleda VG, Barkhatova AN. Neurophysiological characteristics of cognition during first episode in young men with endogenous psychoses. [Article in Russian]. *Zh Nevrol Psikhiatr Im S S Korsakova* 2007;107(2):12-20.
 39. Lebedeva IS, Kaleda VG, Barkhatova AN. Neurophysiological characteristics of cognitive functions in patients with first episodes of endogenous psychosis. *Neurosci Behav Physiol* 2008;38(3):259-67.
<https://doi.org/10.1007/s11055-008-0038-7>.
 40. Bramon E, Dempster E, Frangou S, Shaikh M, Walshe M, Filbey FM, et al. Neuregulin-1 and the P300 waveform—a preliminary association study using a psychosis endophenotype. *Schizophr Res* 2008;103(1-3):178-85.
<https://doi.org/10.1016/j.schres.2008.03.025>.
 41. Shucard JL, McCabe DC, Szymanski H. An event-related potential study of attention deficits in posttraumatic stress disorder during auditory and visual Go/NoGo continuous performance tasks. *Biol Psychol* 2008;79(2):223-33.
<https://doi.org/10.1016/j.biopsycho.2008.05.005>.
 42. Tuter NV. Cognitive evoked potentials in panic disorders. *Zh Nevrol Psikhiatr Im S S Korsakova* 2008;108(8):47-51.
 43. Gordeev SA. P300 component changes of the auditory event-related potential in the patients with typical and atypical panic attacks. [Article in Russian]. *Zh Vyssh Nerv Deiat Im I P Pavlova* 2007;57(2):161-8.
 44. Gordeev SA. Cognitive functions and nonspecific brain systems in patients with panic disorders. [Article in Russian]. *Zh Nevrol Psikhiatr Im S S Korsakova* 2007;107(6):54-60.
 45. Gordeev SA. Cognitive functions and the state of nonspecific brain systems in panic disorders. *Neurosci Behav Physiol* 2008;38(7):707-14.
<https://doi.org/10.1007/s11055-008-9036-z>.
 46. Coullaut-Valera Garcia J, Arbaiza Diaz del Rio I, Coullaut-Valera Garcia R, Ortiz T. Alterations of P300 wave in occipital lobe in depressive patients. *Actas Esp Psiquiatr* 2007;35(4):243-8.
 47. Zhang Y, Hauser U, Conty C, Emrich HM, Dietrich DE. Familial risk for depression and p3b component as a possible neurocognitive vulnerability marker. *Neuropsychobiology* 2007;55(1):14-20.
<https://doi.org/10.1159/000103571>.
 48. Zukov I, Hruby T, Kozelek P, Ptáček R, Paclt I, Harsa P. P300 wave: A comparative study of impulsive aggressive criminals. *Neuro Endocrinol Lett* 2008;29(3):379-84.
 49. Gohle D, Juckel G, Mavrogiorgou P, Pogarell O, Mülert C, Rujescu D, et al. Electrophysiological evidence for cortical abnormalities in obsessive-compulsive disorder - A replication study using auditory event-related P300 subcomponents. *J Psychiatr Res* 2008;42(4):297-303.
<https://doi.org/10.1016/j.jpsychires.2007.01.003>.
 50. Lew HL, Gray M, Poole JH. Temporal stability of auditory event-related potentials in healthy individuals and patients with traumatic brain injury. *J Clin Neurophysiol* 2007;24(5):392-7.
<https://doi.org/10.1097/WNP.0b013e31814a56e3>.
 51. Elting JW, Maurits N, Weerden T, Spikman J, De Keyser J, van der Naalt J. P300 analysis techniques in cognitive impairment after brain injury: Comparison with neuropsychological and imaging data. *Braun Inj* 2008;22(11):870-81.
<https://doi.org/10.1080/02699050802403581>.
 52. Cui Y, Liu F, Zhang XY, Tang P, Liu P, Zhang B, et al. Auditory P300 in the patients with traumatic brain injury. [Article in Chinese]. *Fa Yi Xue Za Zhi* 2009;25(1):19-23.
 53. Lew HL, Gray M, Poole JH. Simultaneous measurement of perceptual and motor cortical potentials: Implications for assessing information processing in traumatic brain injury. *Am J Phys Med Rehabil* 2009;88(1):1-6.
<https://doi.org/10.1097/PHM.0b013e3181911102>.
 54. Guney F, Genc BO, Kutlu R, Ilhan BC. Auditory P300 event-related potential in tobacco smokers. *J Clin Neurosci* 2009;16(10):1311-5.
<https://doi.org/10.1016/j.jocn.2008.11.025>.
 55. Naziel B, Yavas G, Arıkan Z, Ozon O, Aksoy OO, Irkeç C. Event related potentials in children of alcoholics. *Electromyogr Clin Neurophysiol* 2008;47(6):315-8.
 56. Muraire P, Philippot P, Joassin F, Pauwels L, Pham T, Prieto EA, et al. The auditory-visual integration of anger is impaired in alcoholism: An event-related potentials study. *J Psychiatry Neurosci* 2008;33(2):111-22.
<https://doi.org/10.1016/j.jpsycho.2008.05.059>.
 57. Roser P, Juckel G, Rentzsch J, Nadulski T, Gallinat J, Stadelmann AM. Effects of acute oral Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory P300 event-related potential in healthy volunteers. *Eur Neuropsychopharmacol* 2008;18(8):569-77.
<https://doi.org/10.1016/j.euroneuro.2008.04.008>.
 58. Singh SM, Basu D, Kohli A, Prabhakar S. Auditory P300 event-related potentials and neurocognitive functions in opioid dependent men and their brothers. *Am J Addict* 2009;18(3):198-205.
<https://doi.org/10.1080/10550490902786975>.
 59. Gooding DC, Burroughs S, Boutros NM. Attentional deficits in cocaine-dependent patients: Converging behavioral and electrophysiological

- evidence. *Psychiatry Res* 2008;160(2):145-54.
<https://doi.org/10.1016/j.psychres.2007.11.019>.
60. de Sola S, Tarancón T, Pena-Casanova J, Espadaler JM, Langohr K, Poudevida S, et al. Auditory event-related potentials (P3) and cognitive performance in recreational ecstasy polydrug users: Evidence from a 12-month longitudinal study. *Psychopharmacology (Berl)* 2008;200(3):425-37.
<https://doi.org/10.1007/s00213-008-1217-5>.
 61. Sun W, Wang W, Wu X, Wang Y. Antiepileptic drugs and the significance of event-related potentials. *J Clin Neurophysiol* 2007;24(3):271-6.
<https://doi.org/10.1097/WNP.0b013e31803bb334>.
 62. Sun W, Wang Y, Wang W, Wu Y. Attention changes in epilepsy patients following 3-month topiramate or valproate treatment revealed by event-related potential. *Int J Psychophysiol* 2008;68(3):235-41.
<https://doi.org/10.1016/j.ijpsycho.2008.02.003>.
 63. Titlic M, Isgum V, Neseck-Madaric V, Lusic I. The effects of lamictal (lamotrigine) on the cognitive functions in patients suffering from epilepsy. *Eur J Neurology* 2005;12(Suppl 2):92.
 64. Otero GA, Pliego-Rivero FB, Porcayo-Mercado R, Medieta-Alcántara G. Working memory impairment and recovery in iron deficient children. *Clin Neurophysiol* 2008;119(8):1739-46.
<https://doi.org/10.1016/j.clinph.2008.04.015>.
 65. Khedr E, Hjamed SA, Elbeih E, El-Shereef H, Ahmad Y, Ahmed S. Iron states and cognitive abilities in young adults: Neuropsychological and neurophysiological assesment. *Eur Arch Psychiatry Clin Neurosci* 2008;258(8):489-96.
<https://doi.org/10.1007/s00406-008-0822-y>.
 66. Kececi H, Degirmenci Y. Quantitative EEG and cognitive evoked potentials in anemia. *Neurophysiol Clin* 2008;38(2):137-43.
<https://doi.org/10.1016/j.neucli.2008.01.004>.
 67. Reeves RR, Struve FA, Rash CJ, Burke RS. P300 cognitive evoked potentials before and after liver transplantation. *Metab Brain Dis* 2007;22(2):139-44.
<https://doi.org/10.1007/s11011-007-9055-4>.
 68. Teodoro V, Bragagnolo Jr M, Lucchesi L, Kondo M, Tufik S. Evaluation of the event-related potential (ERP-P300) in patients with hepatic cirrhosis without encephalopathy. *Arq Gastroenterol* 2008;45(1):82-6.
<https://doi.org/10.1590/S0004-28032008000100015>.
 69. Guerit JM, Amantini A, Fischer C, Kaplan PW, Mecarelli O, Schnitzler A, et al. Neurophysiological investigations of hepatic encephalopathy: ISHEN practice guidelines. *Liver Int* 2009;29(6):789-96.
<https://doi.org/10.1111/j.1478-3231.2009.02030.x>.
 70. Mostafa GA, Nazif HK, El-Shahawi HH, Abd El-Aziz MM, Hassan MA. Antineuronal antibodies and electroneurophysiological studies in pediatric patients with neuropsychiatric systemic lupus erythematosus. *Pediatr Allergy Immunol* 2009;20(2):192-9.
<https://doi.org/10.1111/j.1399-3038.2008.00753.x>.
 71. Buca A, Perkovic D, Martinovic-Kaliterna D, Vlastelica M, Titlic M. Neuropsychiatric systemic lupus erythematosus: Diagnostic and clinical features according to revised ACR criteria. *Coll Antropol* 2009;33(1):281-8.
 72. Madan P, Agarwal S, Kalra OP, Tandon OP. Effect of hemodialysis on cognitive function in ESRD patients. *Ren Fail* 2007;29(6):699-703.
<https://doi.org/10.1080/08860220701460103>.
 73. Cooray GK, Maurex L, Brismar T. Cognitive impairment correlates to low auditory event-related potential amplitudes in type 1 diabetes. *Psychoneuroendocrinology* 2008;33(7):942-50.
<https://doi.org/10.1016/j.psyneuen.2008.04.013>.
 74. Nazliel B, Yilmaz M, Kocer B, Yetkin I, Yesilbudak Z. Event related potentials in hypothyroidism. *Electromyogr Clin Neurophysiol* 2008;48(5):203-8.
 75. Anjana Y, Tandon OP, Vaney N, Madhu SV. Cognitive status in hypothyroid female patients: Event-related evoked potential study. *Neuroendocrinology* 2008;88(1):59-66.
<https://doi.org/10.1159/000117713>.
 76. Kirkil G, Tug T, Ozel E, Bulut S, Tekatas A, Muz MH. The evaluation of cognitive functions with P300 test for chronic obstructive pulmonary disease patients in attack and stable period. *Clin Neurol Neurosurg* 2007;109(7):553-60.
<https://doi.org/10.1016/j.clineuro.2007.03.013>.
 77. Dassanayake T, Weerasinghe V, Dangahadeniya U, Kularatne K, Dawson A, Karaliedde L, et al. Long-term event-related potential changes following organophosphorus insecticide poisoning. *Clin Neurophysiol* 2008;119(1):144-50.
<https://doi.org/10.1016/j.clinph.2007.09.134>.
 78. Amador Romero F, Pelegina del Rio M, Mayor Rios J. Cognitive slowing in cognitive-motor disorder associated to type 1 human immunodeficiency virus: TR and P300. *Actas Esp Psiquiatr* 2007;35(4):221-8.
 79. Scott GG, O'Donnell PJ, Leuthold H, Serono SC. Early emotion word processing: Evidence from event-related potentials. *Biol Psychol* 2009;80(1):95-104.
<https://doi.org/10.1016/j.biopsycho.2008.03.010>.
 80. Mantini D, Corbetta M, Perrucci MG, Romani GL, Del Gratta C. Large-scale brain networks account for sustained and transient activity during target detection. *Neuroimage* 2009;44(1):265-74.
<https://doi.org/10.1016/j.neuroimage.2008.08.019>.
 81. Schiff S, Valenti P, Andrea P, Lot M, Bisiacchi P, Gatta A, et al. The effect of aging on auditory components of event-related brain potentials. *Clin Neurophysiol* 2008;119(8):1795-802.
<https://doi.org/10.1016/j.clinph.2008.04.007>.
 82. Saillas E, El Yagoubi R, Semenza C. Sensory and cognitive processes of shifts of spatial attention induced by numbers: An ERP study. *Cortex* 2008;44(4):406-13.
<https://doi.org/10.1016/j.cortex.2007.08.006>.
 83. Sawaki R, Katayama J. Distractor P3 is associated with attentional capture by stimulus deviance. *Clin Neurophysiol* 2008;119(6):1300-9.
<https://doi.org/10.1016/j.clinph.2008.01.107>.